| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_221216c741ab62bd811fbdd2e59c9ca2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aab0bbfdf8e36e67141db20b9c01265a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_17cce8a16238c53d16e9a4240e88abea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_233d87434a1859a2147a1b752b942f1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ef2a06d7c1e491f1eafa6dd9d1e3afe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a2919a384e8471477b61879f48477938 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-07 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C303-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C231-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C303-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C303-44 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C303-40 |
| filingDate |
2006-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7254a1adc937af46b96a2176267373e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aceb71683d7abc16bcb71c8c14bce025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_becc766e60d1ef2069d351ece2b523c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92d70695efb77d0447e4103327d5ce00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30f42884533f7771121be463937a7270 |
| publicationDate |
2007-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2007086074-A2 |
| titleOfInvention |
A process for the preparation of r (-) tamsulosin hydrochloride |
| abstract |
The invention discloses a process for the preparation of highly pure R (-)-5-(2-(2-(2-ethoxy phenoxy) ethylamine) propyl)-2-methoxy benzene sulfonamide hydrochloride used to treat symptoms of urinary difficulty. R-(-)-2-(4-methoxy phenyl)- 1 -methyl ethyl amine is condensed with halo-acetyl halide in the presence of base and a halogenated solvent. The resulting R-(-)- halo-N-[2-(4-methoxy phenyl)- 1 -methyl ethyl] acetamide is treated with chlorosulphonic acid and ammonia. R-(-)-N-[2-(3-amino sulfonyl-4-methoxy phenyl)- 1 -methyl ethyl]-2- haloacetamide obtained is treated with 2- ethoxy phenol in the presence of an inorganic base and water to obtain R-(-)-N-[2-(3-amino sulfonyl-4-methoxy phenyl)- 1 -methyl ethyl]-2-(2- ethoxy phenoxy) acetamide in high yield and purity. The amide obtained is reduced to obtain the Tamsulosin base, which is then purified and converted to its hydrochloride salt. |
| priorityDate |
2006-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |